Ken Griffin Aadi Bioscience, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,900 shares of AADI stock, worth $9,359. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,900
Previous 11,400
57.02%
Holding current value
$9,359
Previous $23,000
52.17%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AADI
# of Institutions
64Shares Held
13.7MCall Options Held
4.9KPut Options Held
700-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.44 Million0.08% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.53 Million3.54% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.11 Million4.26% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA857KShares$1.64 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $40.1M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...